期刊文献+

化浊解毒方联合西药治疗冠心病“易损血液”浊毒证临床观察 被引量:1

Observation on Clinical Effect of Hua-Zhuo-Jie-Du Decoction in Treatment of Coronary Heart Disease “Vulnerable Blood”with Turbidity Toxin Syndrome
下载PDF
导出
摘要 目的:观察化浊解毒方治疗冠心病"易损血液"浊毒证的临床疗效。方法:随机将120例冠心病"易损血液"浊毒证患者分为对照组60例和试验组60例,对照组予常规西医治疗,试验组在对照组用药基础上加用化浊解毒方,水煎600 mL,1剂/d,分早晚2次服用。4 w后比较2组治疗前后临床证候变化。结果:2组临床证候疗效比较有显著性差异(P<0.05)。结论:化浊解毒方联合西药能够有效改善冠心病"易损血液"浊毒证临床证候。 Objective: To observe the clinical effect of Hua-zhuoojie-du decoction in the treatment of coronary heart disease "vulnerable blood" with turbidity toxin syndrome. Methods: 120 patients with coronary heart disease "vulnerable blood" with turbidity toxin syndrome were randomly divided into control group ( n = 60) treated with routine western medicine and trial group treated with routine western medicine and Hua-zhuo-jie-du decoction for 4 weeks. Clinical syndrome was compared of two groups before and after treatment. Results : Clinical syndrome levels in trial group were lower than that in the control group ( P 〈 0. 05 ) . Conclusion: Hua- zhuo-jie-du decoction can effectively treat the coronary heart disease "vulnerable blood" with turbidity toxin syndrome.
出处 《成都中医药大学学报》 2014年第2期83-85,共3页 Journal of Chengdu University of Traditional Chinese Medicine
基金 青岛市卫生局中医科研计划(编号:2013zyy-024)
关键词 化浊解毒方 冠心病 易损血液 浊毒证 疗效观察 Hua-zhuo-jie-du decoction coronary heart disease vulnerable blood turbidity toxin syndrome curative effect observation
  • 相关文献

参考文献5

二级参考文献54

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2南京中医学院编.难经校释[M].北京:人民卫生出版社,1979:102-103.
  • 3王纶.名医杂著[M].南京:江苏科学技术出版社,1985:31.
  • 4许慎.说文解字[M].北京:中华书局,1987.
  • 5商务印书馆编辑部.辞源:第2册[M].北京:商务印书馆,1980:1693.
  • 6Kaiser D, Freyberg M A, Friedl P. Lack of hemodynamic forces triggers apoptosis in vascular endothelial cells. Biochem Biophys Res Commun, 1997, 231: 586-590.
  • 7Koenig W, Sund M, Lowel H, et al. Association between plasma viscosity and all-cause mortality: results from the MONICA-Augsburg Cohort Study 1984-1992. Br J Haematol, 2000, 109: 453-458.
  • 8Agati L. Microvascular integrity after reperfusion therapy. Am Heart J, 1999, 138(2 Pt 2): S76-S78.
  • 9Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient-a call for new definitions and risk assessment strategies: part Ⅱ. Circulation, 2003, 108:1772-1778.
  • 10Shah S, Newby L K. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev, 2003, 11: 169-179.

共引文献2265

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部